Skip to content
Engineering, Medical Health Aged Care

Solar panels in your eyeballs? This engineer is looking into it

UNSW Sydney 3 mins read

UNSW engineers are examining ways that solar panels can be implanted in the human retina to restore sight.

 

Neuroprosthetics – or devices designed to interact with the nervous system to restore lost functionality – is a developing area of research that has the potential to vastly improve quality of life.

One of the best-known examples is the cochlear implant which converts sound into electric signals that directly stimulate the auditory nerve in people with severe hearing loss.

But could the same be done for the human eye to restore vision for people with damaged photoreceptors – the cells responsible for detecting light and colour? A multidisciplinary group of researchers across the globe including engineers, neuroscientists, clinicians and other biotech experts believe it can – but it’s a case of baby steps for now.

UNSW researcher Dr Udo Roemer is an engineer who specialises in photovoltaics, known more commonly as solar panel technology. He is in the early stages of researching how solar technology can be used to convert light entering the eye into electricity, bypassing the damaged photoreceptors to transmit visual information to the brain.

“People with certain diseases like retinitis pigmentosa and age-related macular degeneration slowly lose their eyesight as photoreceptors at the centre of the eye degenerate,” Dr Roemer says.

“It has long been thought that biomedical implants in the retina could stand in for the damaged photoreceptors. One way to do it is to use electrodes to create voltage pulse that may enable people to see a tiny spot.

“There have already been trials with this technology. But the problem with this is they require wires going into the eye, which is a complicated procedure.”

 

Wireless option

But an alternative idea is to have a tiny solar panel attached to the eyeball that converts light into the electric impulse that the brain uses to create our visual fields. The panel would be naturally self-powered and portable, doing away for the need to have cables and wires into the eye.

Dr Roemer isn’t the first to investigate the use of solar cells assisting in restoring sight. But rather than focus on silicon-based devices, he has turned his attention to other semiconductor materials such gallium arsenide and gallium indium phosphide, mainly because it’s easier to tune the materials’ properties. It’s also used in the solar industry at large to make much more efficient solar panels, although it’s not as cheap as the all-purpose silicon.

“In order to stimulate neurons, you need a higher voltage than what you get from one solar cell,” Dr Roemer says.

“If you imagine photoreceptors being pixels, then we really need three solar cells to create enough voltage to send to the brain. So we’re looking at how we can stack them, one on top of the other, to achieve this.

“With silicon this would have been difficult, that’s why we swapped to gallium arsenide where it’s much easier.”

So how far along is this research? Dr Roemer says it’s in the proof-of-concept stage.

“So far we’ve successfully put two solar cells on top of each other in the lab on a large area – about 1cm2, which has got some good results.”

The next step will be to make them into the tiny pixels required for sight, and etching the grooves to separate them. It will then be a small step to increase the stack to three solar cells.

Dr Roemer envisages by the time this technology will be able to be tested in humans – after extensive testing in the lab, followed by testing in animal models – the device will be about 2 mm2 in size with pixels measuring about 50 micrometres (five hundredths of a millimetre). He stresses that it’s still a way down the track before this technology will be implantable in the retinas of people with degenerative eye diseases.

“One thing to note is that even with the efficiencies of stacked solar cells, sunlight alone may not be strong enough to work with these solar cells implanted in the retina,” he says.

“People may have to wear some sort of goggles or smart glasses that work in tandem with the solar cells that are able to amplify the sun signal into the required intensity needed to reliably stimulate neurons in the eye.”


Contact details:

Lachlan Gilbert

UNSW News & Content

t: +61 404 192 367

e: lachlan.gilbert@unsw.edu.au

More from this category

  • Engineering, Oil Mining Resources
  • 13/09/2024
  • 12:45
UNSW Sydney

UNSW to lead Australian consortia to progress next steps in hydrogen and green metals collaboration between Australia and Germany

UNSW Sydney researchers have released a firstreportexploring the feasibility of collaboration on hydrogen and green metals, as part of the Federal government’sGreen Metals for Sustainable Steel from Australia and Germany(SuSteelAG) initiative. The project – a partnership between the Australian Department of Climate Change, Energy, the Environment and Water (DCCEEW) and the German Federal Ministry of Education and Research (BMBF) – aims to explore the potential of creating a sustainable green iron and steel value chain between the two countries. It builds upon the UNSW-led ‘HySupply’ study that’s investigating the viability of a closer collaboration on renewable hydrogen supply. Together, Australia…

  • Medical Health Aged Care
  • 13/09/2024
  • 12:40
Zenas BioPharma

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Zenas. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $225.0 million. Zenas’ common stock is expected to begin trading…

  • Medical Health Aged Care
  • 13/09/2024
  • 12:31
Dementia Australia

New report reinforces dementia as chronic disease of 21st century

Updates to the Dementia in Australia report, released today by the Australian Institute of Health and Welfare (AIHW), reinforce that dementia is an urgent public health issue. Dementia is the second leading cause of death in Australia, the leading cause of death of women, the second leading cause of disease burden overall, and the leading cause of burden for people aged 65 and over. Dementia Australia CEO Professor Tanya Buchanan saidthe report highlights the enormity and impact of dementia in Australia as the chronic disease of the 21st century. “Despite the growing number of Australians diagnosed with dementia – there…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.